Generate Biomedicines
GENB
86 hedge funds and large institutions have $1.69B invested in Generate Biomedicines in 2026 Q2 according to their latest regulatory filings, with 42 funds opening new positions, 24 increasing their positions, 10 reducing their positions, and 13 closing their positions.
223% more first-time investments, than exits
New positions opened: 42 | Existing positions closed: 13
140% more repeat investments, than reductions
Existing positions increased: 24 | Existing positions reduced: 10
51% more funds holding
Funds holding: 57 → 86 (+29)
46% more capital invested
Capital invested by funds: $1.16B → $1.69B (+$530M)
5.21% more ownership
Funds ownership: 72.83% → 78.04% (+5.2%)
0% more funds holding in top 10
Funds holding in top 10: 4 → 4 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$22.6M |
| 2 |
DTC
Deep Track Capital
Greenwich,
Connecticut
|
+$18.2M |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
+$13.7M |
| 4 |
Vanguard Capital Management
Malvern,
Pennsylvania
|
+$13.6M |
| 5 |
AIM
ARK Investment Management
St. Petersburg,
Florida
|
+$10.7M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
JP Morgan Chase
New York
|
-$20.9M |
| 2 |
Alyeska Investment Group
Chicago,
Illinois
|
-$6.25M |
| 3 |
Millennium Management
New York
|
-$4.84M |
| 4 |
B
Braidwell
Stamford,
Connecticut
|
-$4.21M |
| 5 |
ECM
ExodusPoint Capital Management
New York
|
-$3.9M |
GENB Hedge Fund Activity: Q2 2026 in Review
86 of the 8,320 institutional investors tracked by Wall St. Rank reported a position in Generate Biomedicines (GENB) for Q2 2026, worth a combined $1.69B — up 46% from $1.16B a quarter earlier.
Buyers outnumbered sellers: 42 funds opened new GENB positions and 13 closed out — a net gain of 29 holders — while 24 added to existing stakes and 10 trimmed.
The largest buyer was BlackRock, opening a new position worth an estimated $22.6M. The largest seller was JP Morgan Chase, cutting an estimated $20.9M.
- 86 institutional investors held Generate Biomedicines (GENB) as of Q2 2026, up from 57 in Q1 2026.
- Funds reported $1.69B of Generate Biomedicines stock for Q2 2026, up 46% quarter-over-quarter.
- 42 funds opened new Generate Biomedicines positions in Q2 2026 and 13 closed out, a net change of +29 holders.
- The largest Generate Biomedicines buyer in Q2 2026 was BlackRock, an estimated $22.6M added.
- The largest Generate Biomedicines seller in Q2 2026 was JP Morgan Chase, an estimated $20.9M sold.
Based on aggregated 13F filings for Q2 2026.